Frequently Asked Questions on Breast Cancer Patient Support, Self-Advocacy, and Survivorship

Self-advocacy, peer community, and attention to the mental and physical realities of cancer survivorship are as central to breast cancer care as the treatments themselves, according to Sara Nunnery, MD, MSCI, and patient advocate Annie Bond.

Although much of the oncology field’s attention goes to drugs and data, the questions patients most often struggle with are about how to be heard, how to find support, and how to live well after a diagnosis, especially for the growing number of patients diagnosed at a young age or with metastatic disease.

Speaking on an episode of the Breast Cancer Briefing podcast, Nunnery and Bond discussed how patients and advocates can navigate second opinions, fertility preservation, community and mental health support, and the long-term effects of treatment, drawing on Bond’s experience as a 10-year survivor of de novo metastatic breast cancer diagnosed at age 26. This FAQ reframes that conversation as a practical resource for patients, advocates, and the clinicians who support them.

Nunnery is a breast medical oncologist, the director of Breast Cancer Research at Tennessee Oncology in Nashville, Tennessee, and the host of Breast Cancer Briefing. Bond is a breast cancer survivor, patient advocate, comedian, and content creator who shares her experience living with metastatic disease to promote early detection and support for others.

Q: Why does self-advocacy matter so much at diagnosis, particularly for younger patients?

A: Younger patients are still too often reassured that they are “too young” to have breast cancer. Bond’s concerns about a breast lump were repeatedly dismissed on the basis of her age and lack of family history, and it took approximately 9 months of persistence, as well as a clinician who pushed for an ultrasound, before she was diagnosed, by which point the disease had spread to her liver. Notably, breast cancer incidence rose by about 1% annually from 2012 to 2021, with a steeper increase among women younger than 50 years (1.4% per year) than among those 50 years and older (0.7% per year).¹

Patients should also know that breast cancer does not always present as a classic lump. “Breast cancer can present in many different ways,” Nunnery said, including “a change in the shape of the breast, change of the skin or texture, or anything that’s new and different for you.”

Q: When should a patient seek a second (or third) opinion, and how can they do so without fear of offending their oncologist?

A: Both experts agreed that patients should seek second opinions whenever the plan does not make sense to them or they do not feel comfortable with their clinician. Bond saw 3 oncologists before she felt she understood her own disease; the third took the time to explain why her treatment would follow a particular path.

“Cancer is an art in a way, because it is so complex and it is so individual,” she said, adding that, “bedside manner matters, and the way that you communicate to patients matters, because we need to understand. You have time to get another opinion. You’re not going to upset your doctor. If it does upset your doctor, it’s probably not the right doctor.”

Nunnery echoed this, saying, “no one should feel ashamed of getting a second opinion. I would rather you have a doctor who you feel really comfortable with.”

A second opinion can also change disease management. Bond’s third oncologist recommended a CDK4/6 inhibitor rather than immediate chemotherapy on the basis of her luminal A (hormone receptor [HR]–positive, HER2-negative) disease subtype, an approach consistent with the evidence that endocrine therapy plus ovarian suppression and a CDK4/6 inhibitor is a preferred first-line standard of care for premenopausal patients with HR-positive/HER2-negative advanced disease.

Q: What should patients know about fertility preservation, and how can they advocate for it?

A: Fertility preservation is time-sensitive, and conversations surrounding this should happen before gonadotoxic therapy begins. Bond was not counseled about fertility by her first oncologist; a nurse raised it during an unrelated visit, and when Bond pursued egg freezing, her oncologist discouraged the process. She froze her eggs anyway, although on a compressed timeline. Her takeaway for patients is to treat fertility preservation as one of the options they are entitled to consider, and to seek a reproductive specialist referral early, before starting treatment. Oncologists should raise the topic of fertility preservation proactively with every patient of reproductive age at diagnosis and connect them quickly with reproductive endocrinology specialists and nonprofit programs that help offset costs, since the window to act is short.

Q: How can patients with cancer find community and peer support?

A: Patients can find support through hospital-based and virtual support groups, peer-matching organizations, and social media. Bond described sitting in her first young-survivor support group and hearing others voice the exact thoughts she had been afraid to say aloud, which made her feel, for the first time, that her reactions were valid.

Practical avenues toward support include the following:

• Hospital or center-based support groups, many now offered virtually, which lower the barrier of leaving home
• One-to-one peer matching, which pairs patients with someone of a similar age, or someone who has a similar diagnosis or disease subtype
• Clinician-facilitated connections, which involves, with patients’ permission, pairing 2 patients with similar diagnoses, something Bond’s own oncologist did for her
• Online communities and advocates, which can be especially valuable for patients with metastatic disease, who may feel isolated in groups oriented toward early-stage survivors.

Q: How should the mental health burden of cancer survivorship be addressed?

A: The effects of cancer on mental health should be addressed proactively, repeatedly, and without the expectation that patients perform strength or gratitude. Bond pushed back on the “warrior” framing, saying that patients “should not feel the pressure to be a warrior when you’re going through cancer treatment, because nothing will make you feel weaker.” She described guilt, shame, and post-traumatic stress disorder that manifested physically, and noted that distress does not end when treatment stabilizes because “survivorship is a whole different battle.” She emphasized that psychological distress in this population can be life-threatening and warrants the same seriousness as any treatment complication.

Effective supports include individual therapy, peer community, and, when appropriate, pharmacologic treatment, ideally coordinated with the oncology team. Clinicians should screen for distress routinely and keep offering resources even when it feels repetitive, Nunnery said.

“Sometimes you’re like, am I being a broken record by asking them all the time about mental health?” Nunnery noted. “But you never know when that moment will come where a patient could really use that.”

Q: What are practical strategies for managing the long-term physical effects of cancer treatment?

A: Anticipatory counseling plus specific, evidence-based management are crucial, since effects such as medical menopause, genitourinary symptoms, cognitive changes, and joint pain can persist for years. Nunnery noted that menopausal symptoms are among the hardest effects to prepare patients for, since symptoms can range from minimal to debilitating. For genitourinary syndrome of menopause, options discussed included low-dose topical/vaginal therapies and nonhormonal approaches, such as hyaluronic acid–based products. Both speakers emphasized that decisions about local vaginal estrogen in HR-positive disease should be individualized with the oncology team. Patients may also describe “menopause brain” and trauma-related cognitive changes, an area that both speakers acknowledged is under-researched and under-supported.

For endocrine therapy–associated joint pain, exercise has been shown to benefit. This aligns with Bond’s experience; she manages joint pain and mental health together through walking and stretching, noting that even 10 minutes of walking helps.

Q: How can clinicians challenge misconceptions about cancer that may lead patients to blame themselves for their diagnosis?

A: The oncology field should shift the framing around cancer from prevention to early detection. Bond described how a false sense of security—being young, healthy, and without a family history—delayed her own diagnosis, and how blame narratives around diet and alcohol fueled guilt and, in her community, disordered eating. The reality is that most patients diagnosed with breast cancer have no family history of the disease, and only a minority of cases are attributable to inherited gene mutations; the majority arise in women without identifiable hereditary risk.

“It was much easier to blame myself than it was to look at the reality,” Bond said. “But the reality is freeing, because the truth is the truth.”

Clinicians should normalize performing cancer risk assessments and density-informed screenings. As of September 2024, the FDA requires nationwide breast density notification in mammography reports. Additionally, validated risk models, such as the Tyrer-Cuzick model and emerging artificial intelligence–based tools, incorporate breast density and individual factors beyond family history.² Reflecting the rise in younger-onset disease, the US Preventive Services Task Force lowered the recommended age to begin screening to 40 years in 2024.¹

Bond and Nunnery also underscored the importance of promoting body awareness without shame. Ultimately, framing cancer risk as partly outside a patient’s control, Bond argued, is more honest and less harmful than implying that lifestyle alone determines who gets the disease.

Q: What can cancer health care providers and patient advocates do to keep patients connected to support?

A: Keep offering support, keep asking how support can be given, and treat connection as part of treatment, Bond said. She emphasized that it takes courage for patients to ask for help, so the responsibility should not rest solely with them; clinicians should repeatedly raise mental health, facilitate peer introductions, and point to specific organizations. She also made the case that survivorship support for patients with metastatic disease depends on visibility and funding.

“There is no way we can stop breast cancer deaths without education about metastatic breast cancer, and without funding for metastatic breast cancer research,” Bond stated.

Additionally, for patient advocates, sharing honest, hopeful stories, including that long-term survival with metastatic disease is possible, counters the fatalism that a statistic alone can impose and helps newly diagnosed patients see a future.

References

1. Giaquinto AN, Sung H, Newman LA, et al. Breast cancer statistics, 2024. CA Cancer J Clin. 2024;74(6):477-495. doi:10.3322/caac.21863
2. Frequently asked questions about MQSA. US Food and Drug Administration. Accessed October 16, 2026. https://www.fda.gov/radiation-emitting-products/mammography-information-patients/frequently-asked-questions-about-mqsa